LARVOL is pleased to present a moderated discussion with top oncologists following IASLC 2021 World Conference on Lung Cancer. In the video below, Dr. Mark Awad, Dr. Ticiana Leal and Dr. Joshua Reuss discuss the practice-changing impact of WCLC presentations in Lung cancer.
On September 16th, 2021, LARVOL hosted an Oncology Panel to discuss the top Lung Cancer clinical trial abstracts presented during the IASLC 2021 World Conference on Lung Cancer, held on September 8-14, 2021. Dr. Mark Awad from Dana-Farber Cancer Institute moderated the discussion between Lung Cancer experts Dr. Ticiana Leal from Emory University School of Medicine and Dr. Joshua Reuss from Georgetown Lombardi Cancer Center.
The discussion covered WCLC Abstracts:
• OA15.03: Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
• PL02.05: IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
• PL02.01: Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
Watch this video for the full discussion:
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.